Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate osteopathy, does it exist?

K Maenaut1, R Westhovens, J Dequeker

  • 1Department of Internal Medicine, K. U. Leuven, Pellenberg, Belgium.

The Journal of Rheumatology
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Flemish network on rare connective tissue diseases (CTD): patient pathways in systemic sclerosis. First steps taken.

Acta clinica Belgica·2023
Same author

Development and validation of a screening tool for SPondyloArthritis Screening in Sub-Saharan Africa: SpASSS questionnaire.

BMC medical research methodology·2023
Same author

Belgian rheumatologists' preferences regarding measures of disease activity in patients with rheumatoid arthritis: results from a mixed-methods study.

Rheumatology international·2021
Same author

Tapering of Etanercept is feasible in patients with Rheumatoid Arthritis in sustained remission: a pragmatic randomized controlled trial.

Scandinavian journal of rheumatology·2021
Same author

Does opioid-based pharmacotherapy have a place in rheumatoid arthritis therapy?

Expert opinion on pharmacotherapy·2021
Same author

A systematic review on the effect of DMARDs on fertility in rheumatoid arthritis.

Seminars in arthritis and rheumatism·2020
Same journal

Clinical Features and Outcome Measures Across Still Disease (Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still Disease) Cohorts Worldwide: A Systematic Literature Review.

The Journal of rheumatology·2026
Same journal

Concurrent Calcium Pyrophosphate Deposition Disease and Gout of the Cervical Spine Presenting With Subacute Neck Pain and Radiculopathy.

The Journal of rheumatology·2026
Same journal

The Need for Weight Communication Guidelines in Pediatric Rheumatology.

The Journal of rheumatology·2026
Same journal

Bimekizumab Improves Health Status and Work Productivity, With Reduced Productivity Costs, to 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis.

The Journal of rheumatology·2026
Same journal

Qualitative Analysis of Physical Activity Engagement in Women with Self-Reported SLE: The Role of Symptoms, Healthcare Providers, and the Environment.

The Journal of rheumatology·2026
Same journal

Tumoral Calcinosis-like Calcification of the Proximal Interphalangeal Joint Mimicking Rheumatoid Arthritis Flare.

The Journal of rheumatology·2026
See all related articles

Low-dose methotrexate (MTX) may increase fracture risk in rheumatoid arthritis (RA) patients. This "methotrexate osteopathy" suggests caution in those with existing osteoporosis risk factors.

Area of Science:

  • Rheumatology
  • Bone Metabolism
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting joints.
  • Methotrexate (MTX) is a common disease-modifying antirheumatic drug (DMARD) used for RA.
  • Long-term MTX use can impact bone health.

Observation:

  • Two postmenopausal women with RA experienced fractures while on weekly low-dose MTX.
  • These fractures occurred despite RA treatment.

Findings:

  • Low-dose MTX regimens may negatively affect bone metabolism, a condition termed "methotrexate osteopathy."
  • Methotrexate may act as an additional risk factor for osteoporosis and subsequent fractures in RA patients.
  • The risk is particularly relevant in postmenopausal women.

Related Experiment Videos

Implications:

  • Consider "methotrexate osteopathy" in RA patients presenting with fractures.
  • MTX therapy may require careful consideration in patients with multiple osteoporosis risk factors.
  • Further research into MTX's long-term effects on bone density in RA is warranted.